NZ Medicinal Cannabis Licence Requirements 2026: 5 Activity Types, Eligibility & Fees

Five activity types, one regulator, one application form. The cost of getting the scope wrong is a non-refundable NZD $2,587.50.

An NZ medicinal cannabis licence is the gating document for any commercial cannabis activity under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. The scheme runs through the Medicinal Cannabis Agency (MCA) inside Manatū Hauora (Ministry of Health), with Medsafe handling GMP separately for any operator that processes or manufactures product. This article walks through the five licence activity types, the eligibility test the MCA applies to applicants, the fee structure, and the realistic application timeline so you can pick the right scope before you submit.

For the full compliance picture beyond the licence application itself, our NZ medicinal cannabis compliance checklist covers GACP, GMP, MQS testing, security, traceability, and the July 2024 export amendments end to end.

What Is the NZ Medicinal Cannabis Licence System?

The NZ medicinal cannabis licence system was established by the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (SL 2019/231), which came into force on 1 April 2020. It replaced a pre-2020 framework where the only legal cannabis cultivation was for research and development, and where every named-patient prescription required Ministry of Health pre-approval. The current scheme created a commercial pathway for cultivation, manufacture, and supply of medicinal cannabis products in New Zealand for the first time.

Three regulators sit above any operator in the scheme, and each owns a different piece of the compliance picture:

• Medicinal Cannabis Agency (MCA). A division of Manatū Hauora (Ministry of Health). Issues all five activity-type licences, runs premises inspections, sets the GACP cultivation standard, and operates the Minimum Quality Standard (MQS) verification register. The MCA is the day-to-day regulator for licence holders.
• Medsafe. The NZ medicines regulator. Issues the separate Licence to Manufacture Medicines and Licence to Pack Medicines under the Medicines Act 1981, certifies GMP for any operator that processes dried cannabis or manufactures finished product, and approves medicinal cannabis products for prescription.
• Manatū Hauora (Ministry of Health). Sets policy, enacts the Regulations, and receives the annual stocktake report from every licence holder by 31 January each year. The Director-General of Health is the ultimate authority for licence revocations and Schedule changes.

The legal hierarchy: the Misuse of Drugs Act 1975 makes cannabis a controlled drug; the Misuse of Drugs Amendment Act 2019 carved out medicinal cannabis as a permitted use; the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the operational rules; the Amendment Regulations 2024 (SL 2024/129, in force 5 July 2024) expanded export pathways and added the Regulation 38A personal-import ban; and the Medicines Act 1981 governs Medsafe’s GMP and product-approval workflows in parallel. Operators planning to export medicinal cannabis from New Zealand need both an MCA activity licence and a controlled drug export licence per consignment, with an import licence from the destination country in hand before NZ will issue the export.

Which of the 5 NZ Medicinal Cannabis Licence Activity Types Do You Need?

Regulation 22 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 defines five distinct licence activity types. An operator picks the activities that match their intended scope on a single application; each activity carries its own compliance obligations, and the wrong combination either blocks the work the operator wants to do or pulls them into compliance overhead they did not need.

A few practical pairings show up repeatedly:

• Cultivation + Supply. A grower selling dried flower, fresh material, or extracts onward needs both. Supply alone is not enough to grow; cultivation alone is not enough to sell to another licence holder downstream.
• Possession for Manufacture + Supply. A processor turning bulk biomass into finished oromucosal sprays or capsules needs both, plus the Medsafe manufacturing licence stack.
• Cultivation + Possession for Manufacture + Supply. A vertically integrated operator that grows, processes, and sells everything in-house. Three activities, one application, three sets of compliance overhead.
• Nursery alone. A specialist seed bank that never grows, never processes, never supplies plant material. A genuine narrow-scope operation; rare in practice.

One nuance worth flagging: only the Possession for Manufacture activity triggers GMP and the parallel Medsafe licence stack. Cultivation alone falls under GACP, which is a less onerous standard built for agricultural operations rather than pharmaceutical manufacturing. If a cultivator never processes or extracts, they never need to chase Medsafe certification, which materially reduces the compliance bill.

Who Qualifies for an NZ Medicinal Cannabis Licence?

Eligibility is set out in the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 and is applied to every applicant by the MCA before a premises inspection is scheduled. Failing eligibility is the single most common reason a fee gets retained without a licence being issued, because the test is binary and applied at intake.

The current eligibility criteria for a natural-person applicant:

• Aged 18 or over and resident in New Zealand. The MCA accepts permanent residents and citizens. Visitor and temporary work visas do not satisfy the residency test.
• Demonstrated expertise and resources to comply with the Regulations. Applicants must show capability across the activities they intend to conduct: GACP and horticulture knowledge for cultivation, GMP and pharmaceutical experience for manufacture, security infrastructure across all activities. The MCA assesses CVs, organisational charts, SOPs, and facility plans submitted with the application.
• No prior licence revocations under the Misuse of Drugs Act 1975. Any controlled drug licence revoked by the MCA, Medsafe, or any predecessor authority is disqualifying.
• No convictions under the Misuse of Drugs Act 1975, drug-related offences under any other NZ statute, or dishonesty offences under the Crimes Act 1961. Section 217 of the Crimes Act 1961 defines “dishonesty offence” broadly, including theft, fraud, false statement, and forgery. The MCA runs a NZ Police check on every applicant.
• No equivalent overseas convictions or revocations. An applicant with a controlled-drug or dishonesty conviction in any jurisdiction is treated the same as one with a NZ conviction. The applicant is responsible for declaring overseas convictions; failure to declare is itself a basis for refusal or later revocation.

For body-corporate applicants (companies, partnerships, trusts), the same criteria apply to every director and partner. A single director with a disqualifying conviction blocks the whole entity. This is why most operators run a clean-slate director check before incorporating the licensed company, and why most genuinely build a compliance-first board from the outset rather than retrofitting one later.

The MCA also assesses organisational structure: who the responsible person is for each activity, how decisions flow, and whether security and quality functions are independent of commercial pressure. This is qualitative and where most first-time applicants get push-back, usually requiring a revised organisational chart before the application progresses.

How Much Does an NZ Medicinal Cannabis Licence Cost?

The headline application fee is NZD $2,587.50 including GST, payable to the MCA at the point of submission. This single fee covers the application itself regardless of how many of the five activity types the applicant requests; an integrated cultivation + manufacture + supply application carries the same fee as a nursery-only application.

The fee is non-refundable if the application is declined. If the MCA refuses on eligibility grounds, on premises-inspection failure, or on insufficient evidence of compliance capability, the applicant loses the fee in full. Reapplication requires a fresh fee at the prevailing rate. This is the practical cost of getting eligibility wrong, and the reason most established operators run an internal pre-flight check (eligibility, organisational structure, facility readiness, draft SOPs) before submitting.

The fee is also payable on annual renewal. The licence is not a one-off purchase. Each year the operator submits a renewal application with the same fee, currently NZD $2,587.50 incl GST. Renewal requires the licence to remain in good standing: the annual stocktake (as at 31 December, reported to the Director-General by 31 January) must be filed on time, 5-year record retention must be current, and no outstanding compliance findings from the most recent MCA inspection.

Operators planning a vertically-integrated build should also budget separately for:

• Medsafe Licence to Manufacture Medicines and/or Licence to Pack Medicines. Required only for Possession for Manufacture activities. Separate fees published by Medsafe.
• Controlled drug import/export licences. Required per consignment for cross-border movement. Separate fee per licence.
• MQS verification testing. Required on every product before first supply. Costs depend on product matrix and the GMP-certified lab’s published rates; budget accordingly per product line. See our NZ Minimum Quality Standard cannabis MQS guide for the full test panel.
• HDEC ethics review. Required only for Research activities. Fee set by the Health and Disability Ethics Committee.

The MCA application fee is therefore a small fraction of the true cost of becoming licensed. Premises build-out, security infrastructure, GMP facility design, validated process documentation, and the first round of MQS testing typically dwarf the application fee by two orders of magnitude for a new manufacturer.

How Long Does the NZ Medicinal Cannabis Licence Application Process Take?

The MCA does not publish a fixed statutory timeline for licence assessment, and the actual elapsed time varies with application quality, scope, and inspector availability. Plan for several months for a simple, well-prepared application and up to a year or more for a multi-activity build. The MCA Guideline v3.1 (April 2025) for new product applications gives the most current procedural detail.

The four operational stages every applicant moves through:

1. Application submission. Applicant submits the application form with all supporting documentation (organisational chart, CVs, SOPs, facility plans, security plan, fee). The MCA performs an intake completeness check; incomplete applications are returned without progressing.
2. Eligibility and documentation review. The MCA verifies eligibility (NZ Police check, overseas declarations, director checks for body corporates) and assesses the documentation against the activity types requested. RFIs at this stage each add weeks.
3. Premises inspection. Mandatory before any licence is issued. The MCA inspects the licensed premises against the security, GACP (cultivation), GMP (manufacture), and record-keeping requirements relevant to the activities applied for. Findings either clear the applicant or generate a remediation list to close.
4. Approval and licence issue. Once eligibility is confirmed, documentation accepted, and inspection cleared, the MCA issues the licence with the activities, conditions, and any specific limits noted on the document.

Three factors most commonly extend the timeline beyond the median:

• RFI cycles on documentation. Thin SOPs, missing security plans, or organisational structures that pool QA and commercial decision-making in the same person all generate RFIs. Each round adds 4-8 weeks.
• Premises remediation. Common findings: insufficient detection systems for high-THC cultivars, gaps in 24/7 monitoring coverage, GMP environmental monitoring not yet validated, batch record systems without electronic signatures.
• Multi-activity scope. A combined Cultivation + Possession for Manufacture + Supply application requires the MCA to satisfy itself across three compliance domains plus a Medsafe parallel review for the manufacturing component.

The operator’s planning rule: budget at least 6 months from a clean application to an issued licence for a single-activity cultivation or supply build, and 9-18 months for a manufacturing-inclusive vertical build that requires both MCA and Medsafe sign-off. Building the application package against the full NZ medicinal cannabis compliance checklist before submission is the single biggest lever on shrinking that timeline.